|
Resolution: standard / high Figure 3.
Increases in ACR20, ACR50, and ACR70 scores in patients with rheumatoid arthritis
who failed previous disease-modifying antirheumatic drug therapy and were given one
of four dosages of adalimumab or placebo. Adapted with permission from the BMJ Publishing
Group [32].
Schwartzman et al. Arthritis Res Ther 2004 6(Suppl 2):S3 doi:10.1186/ar1013 |
